Many bioinformatics studies aim to identify markers, or features that can be used to discriminate between distinct groups. In problems where strong individual markers are not available, or where interactions between gene products are of primary interest, it may be necessary to consider combinations of features as a marker family. To this end, recent work proposes a hierarchical Bayesian framework for feature selection that places a prior on the set of features we wish to select and on the label-conditioned feature distribution. While an analytical posterior under Gaussian models with block covariance structures is available, the optimal feature selection algorithm for this model remains intractable since it requires evaluating the posterior over the space of all possible covariance block structures and feature-block assignments. To address this computational barrier, prior work proposes a simple suboptimal algorithm, 2MNC-Robust, with robust performance across the space of block structures. Here, we present three new heuristic feature selection algorithms that outperform 2MNC-Robust on synthetic data. Enrichment analysis on real cancer data indicates that they also output many of the genes and pathways linked to the cancers under study.
a drug response. This problem can often be framed as a feature selection task, where the goal is to identify a list of features (molecular biomarkers) that can discriminate between groups of interest based on high-dimensional data from microarray, RNA-seq, or other high-throughput technologies.
Initially, exploratory studies are often conducted on small samples to generate a shortlist of biomarker candidates before a largesample validation study is performed. However, such studies have too often been unsuccessful at producing reliable and reproducible biomarkers [1] . Biomarker discovery is inherently di cult, given the large number of features, highly complex interactions between genes and gene products, enormous variety of dysfunctions that can occur, and many sources of error in the data. As a result, feature selection algorithms are often implemented without much consideration of the particular demands of the problem. For instance, variants of t-test are perhaps the most widely implemented selection strategies in bioinformatics, but can only detect strong individual features, and fail to take correlations into account.
Given that molecular signaling is often inherently multivariate, there is a need for methods that can account for correlations and extract combinations of features as a marker family. Wrapper methods do this by ranking sets of features according to some objective function, usually the error of a classi er. However, methods based on classi er error are computationally expensive, and may not necessarily produce the best markers; indeed, strong features can be excluded if they are correlated with other strong features. Furthermore, analysis downstream from feature selection may include gene set enrichment analysis, where the hope is to identify known pathways or other biological mechanisms that contain a statistically signi cant number of genes in the reported gene set, or may involve the development of new pathways and gene networks. We are thus motivated to develop methods that not only select markers useful for discrimination, but select all relevant markers, even individually weak ones.
To address this, recent work proposes a hierarchical Bayesian framework for feature selection, labeling features as "good" or "bad", where good features are those we wish to select, i.e., biomarkers. Under independent features, Optimal Bayesian Filtering reports a feature set of a given size with a maximal expected number of true good features (CMNC-OBF) [2] . CMNC-OBF is extremely fast and enjoys particularly excellent performance when markers are individually strong with low correlations, but, like all lter methods, may miss weak features that are of interest due to high correlations with strong features [2, 4] . Assuming good and bad features are separately dependent, 2MNC-Robust proposes an approximation of the posterior on good features and ranks features 4th International Workshop on Computational Network Biology: Modeling, Analysis, and Control (CNB-MAC) ACM-BCB'17, August 20-23, 2017, Boston, MA, USA by evaluating all sets of size 2 [3] . 2MNC-Robust is computationally manageable and generally improves upon CMNC-OBF in the presence of correlations.
Though both algorithms have robust performance across Bayesian models with di erent block-diagonal covariance structures [4] , performance can be improved in the presence of correlation. To this end, we propose three new feature selection algorithms: (1) REcursive MArginal posterior IN ation (REMAIN), which uses an iterative strategy to update the approximate posterior used in 2MNC-Robust, (2) POsterior FActor-Constrained (PO-FAC), which uses a novel scoring function inspired by Bayes factors to improve overall rankings, and (3) Sequential Partition Mustering (SPM), which attempts to detect the underlying block structure of the data.
In the full paper, we discuss the interpretation and e ect of various input parameters to the proposed algorithms, show that these algorithms have comparable computation time to 2MNC-Robust, and provide simulations showing the strengths and weaknesses of each algorithm relative to performance on synthetic Gaussian data with block-diagonal covariance matrices and on synthetic microarray data. In general, the proposed algorithms outperform CMNC-OBF, 2MNC-Robust and many other popular feature selection algorithms. CMNC-OBF is very good at selecting individually strong features, and under non-informative priors typically performs similarly to Bhattacharyya distance under Gaussian distributions with estimated moments. Under small sample sizes, or cases where correctly labeling good features is more di cult, REMAIN tends to output very few features resulting in even better performance, however note that OBF can also enjoy this characteristic if implemented using the unconstrained MNC objective instead of CMNC. SPM is a more complex algorithm that can perform poorly when the sample size is small, possibly due to over-tting or sensitivity to the prior, but has great performance when sample size is large. Finally, POFAC is an interesting option, enjoying competitive performance across all sample sizes. POFAC outperforms 2MNC-Robust with only slightly higher computation cost.
We apply CMNC-OBF, REMAIN, POFAC, and SPM to breast cancer microarray data from [5] , with 119 relapse free patients in class 0 and 40 patients with relapses in class 1. The top ve genes selected by CMNC-OBF, REMAIN and POFAC are provided in Tab. 1. Note SPM outputs feature blocks, not a feature ranking. The top three pathways from enrichment analysis on the gene sets selected by all four algorithms is provided in Tab. 2. Many of these genes and pathways have suggested involvement in breast cancer. In particular, PHTF1, ZNF192, and MUC5AC have been documented in the literature, DCT and ZP2 are high-pro le biomarkers, and the gonadotropin-releasing hormone receptor pathway, ubiquitin proteasome pathway, CCKR signaling map, and integrin signalling pathway have also been linked to breast cancer.
In the full paper, we provide a complete discussion of these results, as well as similar analyses on colon cancer and acute myeloid leukemia datasets. In general, CMNC-OBF tends to nd individually strong markers that already have known involvement in cancer, and might miss biomarkers that are individually weak but heavily correlated with strong biomarkers. Hence, CMNC-OBF may tend to produce strongly annotated genes and pathways, but might not be as useful for discovery. POFAC and REMAIN tend to nd genes that are individually strong or highly correlated with individually strong biomarkers. These algorithms might be more useful in identifying genes directly involved in cancer, or genes that directly interact with them. SPM is speci cally designed to nd all genes correlated with individually strong biomarkers. Hence, it tends to report large gene sets, and may be particularly useful for identifying and hypothesizing which biological functions are a ected in the cancer under study.
